Interview with Ralf Dahmen, Managing Director, Galderma
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
Address: Level 3 21 Solent Circuit BAULKHAM HILLS NSW 2153 AUSTRALIA
,Australia
Tel: 1800 224 321
Web: http://www.novonordisk.com.au/documents/home_page/document/index.asp
At Novo Nordisk, we strive to be the world’s leading diabetes care company, and each of us takes this vision personally. Our highest priority is the health and well being of people living with diabetes. We respect their many lifestyles and individual needs and develop our therapies with those differences in mind.
Through intensive research, Novo Nordisk has created innovative insulin delivery systems as well as disposable needles that were designed to help reduce pain and fear of injection. Using recombinant technology, we have developed novel insulin and insulin analog formulations. We also offer patient education programs, continuing medical education for healthcare professionals, and more, as we strive to meet the individual needs of our customers!
In addition, we hold a leading position in other therapeutic areas, such as coagulation disorders, growth hormone disorders, and hormone therapy for women.
Novo Nordisk has affiliate offices in 81 countries and approximately 27,000 full-time employees worldwide. We reach out to 179 countries around the world with our products and programs. We operate manufacturing facilities in six countries, including the United States.
Novo Nordisk has a comprehensive range of products relating to diabetes, haemostasis, growth and the menopause.
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
See our Cookie Privacy Policy Here
